[Skip to Content]
[Skip to Content Landing]

Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults With Chronic Kidney DiseaseThe CKD WIT Randomized Clinical Trial

Educational Objective
To learn whether coaching to increase water intake can improve kidney function in adults with chronic kidney disease.
1 Credit CME
Key Points

Question  Does drinking more water protect against declining kidney function in patients with chronic kidney disease?

Findings  In this randomized clinical trial that included 631 adult patients with chronic kidney disease, the 1-year decline in estimated glomerular filtration rate did not significantly differ between patients who were coached to drink more water compared with patients who were coached to maintain their usual intake (−2.2 vs −1.9 mL/min per 1.73 m2).

Meaning  Coaching to increase water intake did not significantly slow the decline in kidney function in patients with chronic kidney disease at 1-year follow-up.

Abstract

Importance  In observational studies, increased water intake is associated with better kidney function.

Objective  To determine the effect of coaching to increase water intake on kidney function in adults with chronic kidney disease.

Design, Setting, and Participants  The CKD WIT (Chronic Kidney Disease Water Intake Trial) randomized clinical trial was conducted in 9 centers in Ontario, Canada, from 2013 until 2017 (last day of follow-up, May 25, 2017). Patients had stage 3 chronic kidney disease (estimated glomerular filtration rate [eGFR] 30-60 mL/min/1.73 m2 and microalbuminuria or macroalbuminuria) and a 24-hour urine volume of less than 3.0 L.

Interventions  Patients in the hydration group (n = 316) were coached to drink more water, and those in the control group (n = 315) were coached to maintain usual intake.

Main Outcomes and Measures  The primary outcome was change in kidney function (eGFR from baseline to 12 months). Secondary outcomes included 1-year change in plasma copeptin concentration, creatinine clearance, 24-hour urine albumin, and patient-reported overall quality of health (0 [worst possible] to 10 [best possible]).

Results  Of 631 randomized patients (mean age, 65.0 years; men, 63.4%; mean eGFR, 43 mL/min/1.73 m2; median urine albumin, 123 mg/d), 12 died (hydration group [n = 5]; control group [n = 7]). Among 590 survivors with 1-year follow-up measurements (95% of 619), the mean change in 24-hour urine volume was 0.6 L per day higher in the hydration group (95% CI, 0.5 to 0.7; P < .001). The mean change in eGFR was −2.2 mL/min/1.73 m2 in the hydration group and −1.9 mL/min/1.73 m2 in the control group (adjusted between-group difference, −0.3 mL/min/1.73 m2 [95% CI, −1.8 to 1.2; P = .74]). The mean between-group differences (hydration vs control) in secondary outcomes were as follows: plasma copeptin, −2.2 pmol/L (95% CI, −3.9 to −0.5; P = .01); creatinine clearance, 3.6 mL/min/1.73 m2 (95% CI, 0.8 to 6.4; P = .01); urine albumin, 7 mg per day (95% CI, −4 to 51; P = .11); and quality of health, 0.2 points (95% CI, −0.3 to 0.3; P = .22).

Conclusions and Relevance  Among adults with chronic kidney disease, coaching to increase water intake compared with coaching to maintain the same water intake did not significantly slow the decline in kidney function after 1 year. However, the study may have been underpowered to detect a clinically important difference.

Trial Registration  clinicaltrials.gov Identifier: NCT01766687.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: William F. Clark, MD, Victoria Hospital, 800 Commissioner’s Road E, A2-343, London, ON, Canada N6A 5W9 (william.clark@lhsc.on.ca).

Accepted for Publication: March 29, 2018.

Author Contributions: Drs Clark and Sontrop had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Clark, Sontrop, Huang, Gallo, Moist, House, Weir, Garg.

Acquisition, analysis, or interpretation of data: Clark, Sontrop, Huang, Gallo, House, Cuerden, Weir, Bagga, Brimble, Burke, Muirhead, Pandeya, Garg.

Drafting of the manuscript: Clark, Sontrop, Huang, Garg.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Sontrop, Cuerden, Garg.

Obtained funding: Clark, Sontrop.

Administrative, technical, or material support: Clark, Huang, Gallo, Moist, Weir, Bagga, Burke, Muirhead, Garg.

Supervision: Clark, Huang, Gallo, Moist, Weir, Brimble, Muirhead, Pandeya.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Clark reports receipt of an unrestricted grant, personal fees (scientific advisory board), and travel support from Danone Research. Dr Sontrop reports other (travel support) from Danone Research. Dr Huang reports receipt of a grant from Danone Research. Dr Moist reports other (travel support and serving as chair of the ISN/Danone Hydration for Kidney Health Research Initiative) from Danone Nutrica. No other disclosures were reported.

Funding/Support: This study was funded by Danone Research and the Program of Experimental Medicine, Western University, Canada. Thermo Fisher Scientific provided the instrumentation, assay reagent, and disposables for the analysis copeptin. Dr Garg was supported by the Dr Adam Linton Chair in Kidney Health Analytics, and a Clinician Salary Award from the Canadian Institutes of Health Research.

Role of Funder/Sponsor: Danone Research requested that this study include the measure of creatinine clearance as a secondary outcome; aside from this, the study sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: Michael Walsh, MD, PhD (McMaster University), and Daniel G. Biche, MD (University of Montreal), served on the data and safety monitoring board for this trial. Ivan Tack, MD, PhD (Toulouse Hospital), provided useful insight on renal physiology. None of these individuals received compensation for their contribution. We also acknowledge the 631 patients without whom this investigation would not be possible.

References
1.
Food and Nutrition Board—National Academy of Sciences.  Recommended Dietary Allowances. Natl Res Counc. 1945;No. 122:3-18.
2.
Valtin  H.  “Drink at least eight glasses of water a day.” really? is there scientific evidence for “8 x 8”?  Am J Physiol Regul Integr Comp Physiol. 2002;283(5):R993-R1004.PubMedGoogle ScholarCrossref
3.
Vreeman  RC, Carroll  AE.  Medical myths.  BMJ. 2007;335(7633):1288-1289.PubMedGoogle ScholarCrossref
4.
Lette  F, Dwyer  JP.  The fluid craze.  Lancet. 2008;372(9641):782-784.PubMedGoogle ScholarCrossref
5.
Clark  WF, Sontrop  JM, Huang  S-H, Moist  L, Bouby  N, Bankir  L.  Hydration and chronic kidney disease progression: a critical review of the evidence.  Am J Nephrol. 2016;43(4):281-292.PubMedGoogle ScholarCrossref
6.
Wang  CJ, Grantham  JJ, Wetmore  JB.  The medicinal use of water in renal disease.  Kidney Int. 2013;84(1):45-53.PubMedGoogle ScholarCrossref
7.
Bankir  L, Bouby  N, Ritz  E.  Vasopressin: a novel target for the prevention and retardation of kidney disease?  Nat Rev Nephrol. 2013;9(4):223-239.PubMedGoogle ScholarCrossref
8.
Bouby  N, Bachmann  S, Bichet  D, Bankir  L.  Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat.  Am J Physiol. 1990;258(4 Pt 2):F973-F979.PubMedGoogle Scholar
9.
Clark  WF, Sontrop  JM, Macnab  JJ,  et al.  Urine volume and change in estimated GFR in a community-based cohort study.  Clin J Am Soc Nephrol. 2011;6(11):2634-2641.PubMedGoogle ScholarCrossref
10.
Sontrop  JM, Dixon  SN, Garg  AX,  et al.  Association between water intake, chronic kidney disease, and cardiovascular disease: a cross-sectional analysis of NHANES data.  Am J Nephrol. 2013;37(5):434-442.PubMedGoogle ScholarCrossref
11.
Strippoli  GF, Craig  JC, Rochtchina  E, Flood  VM, Wang  JJ, Mitchell  P.  Fluid and nutrient intake and risk of chronic kidney disease.  Nephrology (Carlton). 2011;16(3):326-334.PubMedGoogle ScholarCrossref
12.
Qaseem  A, Dallas  P, Forciea  MA, Starkey  M, Denberg  TD; Clinical Guidelines Committee of the American College of Physicians.  Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians.  Ann Intern Med. 2014;161(9):659-667.PubMedGoogle ScholarCrossref
13.
Borghi  L, Meschi  T, Amato  F, Briganti  A, Novarini  A, Giannini  A.  Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study.  J Urol. 1996;155(3):839-843.PubMedGoogle ScholarCrossref
14.
Clark  WF, Sontrop  JM, Huang  SH,  et al.  The chronic kidney disease Water Intake Trial (WIT): results from the pilot randomised controlled trial.  BMJ Open. 2013;3(12):e003666.PubMedGoogle ScholarCrossref
15.
Sontrop  JM, Huang  S-H, Garg  AX,  et al.  Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial.  BMJ Open. 2015;5(11):e008634.PubMedGoogle ScholarCrossref
16.
Clark  WF, Huang  S-HS, Garg  AX,  et al.  The Chronic Kidney Disease Water Intake Trial (WIT): protocol of a randomized controlled trial [published online August 22, 2017].  Can J Kidney Heal Dis. doi:10.1177/2054358117725106PubMedGoogle Scholar
17.
Boutron  I, Moher  D, Altman  DG, Schulz  KF, Ravaud  P; CONSORT Group.  Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration.  Ann Intern Med. 2008;148(4):295-309.PubMedGoogle ScholarCrossref
18.
National Kidney Foundation.  KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.  Am J Kidney Dis. 2002;39(2 Suppl 1):S1-S266.PubMedGoogle Scholar
19.
Wang  CJ, Creed  C, Winklhofer  FT, Grantham  JJ.  Water prescription in autosomal dominant polycystic kidney disease: a pilot study.  Clin J Am Soc Nephrol. 2011;6(1):192-197.PubMedGoogle ScholarCrossref
20.
Barash  I, Ponda  MP, Goldfarb  DS, Skolnik  EY.  A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease.  Clin J Am Soc Nephrol. 2010;5(4):693-697.PubMedGoogle ScholarCrossref
21.
Spigt  MG, Knottnerus  JA, Westerterp  KR, Olde Rikkert  MG, Schayck  CP.  The effects of 6 months of increased water intake on blood sodium, glomerular filtration rate, blood pressure, and quality of life in elderly (aged 55-75) men.  J Am Geriatr Soc. 2006;54(3):438-443.PubMedGoogle ScholarCrossref
22.
Levey  AS, Stevens  LA, Schmid  CH,  et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration).  A new equation to estimate glomerular filtration rate.  Ann Intern Med. 2009;150(9):604-612.PubMedGoogle ScholarCrossref
23.
Christ-Crain  M, Fenske  W.  Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis.  Nat Rev Endocrinol. 2016;12(3):168-176.PubMedGoogle ScholarCrossref
24.
Hays  RD, Kallich  J, Mapes  D,  et al.  Kidney Disease Quality of Life Short Form (KDQOL-SF TM), version 1.3. 1997. http://www.rand.org/pubs/papers/P7994.html. Accessed January 12, 2017.
25.
Hays  RD, Kallich  JD, Mapes  DL, Coons  SJ, Carter  WB.  Development of the kidney disease quality of life (KDQOL) instrument.  Qual Life Res. 1994;3(5):329-338.PubMedGoogle ScholarCrossref
26.
Matsushita  K, Selvin  E, Bash  LD, Franceschini  N, Astor  BC, Coresh  J.  Change in estimated GFR associates with coronary heart disease and mortality.  J Am Soc Nephrol. 2009;20(12):2617-2624.PubMedGoogle ScholarCrossref
27.
Turin  TC, Coresh  J, Tonelli  M,  et al.  One-year change in kidney function is associated with an increased mortality risk.  Am J Nephrol. 2012;36(1):41-49.PubMedGoogle ScholarCrossref
28.
Roussel  R, Fezeu  L, Marre  M,  et al.  Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease.  J Clin Endocrinol Metab. 2014;99(12):4656-4663.PubMedGoogle ScholarCrossref
29.
Enhörning  S, Christensson  A, Melander  O.  Plasma copeptin as a predictor of kidney disease [published online February 16, 2018].  Nephrol Dial Transplant. doi:10.1093/ndt/gfy017.PubMedGoogle Scholar
30.
Cravedi  P, Ruggenenti  P, Remuzzi  G.  Proteinuria should be used as a surrogate in CKD.  Nat Rev Nephrol. 2012;8(5):301-306.PubMedGoogle ScholarCrossref
31.
Rosansky  SJ.  Renal function trajectory is more important than chronic kidney disease stage for managing patients with chronic kidney disease.  Am J Nephrol. 2012;36(1):1-10.PubMedGoogle ScholarCrossref
32.
Eriksen  BO, Tomtum  J, Ingebretsen  OC.  Predictors of declining glomerular filtration rate in a population-based chronic kidney disease cohort.  Nephron Clin Pract. 2010;115(1):c41-c50.PubMedGoogle ScholarCrossref
33.
Lorenzo  V, Saracho  R, Zamora  J, Rufino  M, Torres  A.  Similar renal decline in diabetic and non-diabetic patients with comparable levels of albuminuria.  Nephrol Dial Transplant. 2010;25(3):835-841.PubMedGoogle ScholarCrossref
34.
Moher  D, Hopewell  S, Schulz  KF,  et al.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.  BMJ. 2010;340:c869.PubMedGoogle ScholarCrossref
35.
Roy  J, Shou  H, Xie  D,  et al; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.  Statistical methods for cohort studies of CKD: prediction modeling.  Clin J Am Soc Nephrol. 2017;12(6):1010-1017.PubMedGoogle ScholarCrossref
36.
Van Buuren  S, Brand  JPL, Groothuis-Oudshoorn  CGM, Rubin  DB.  Fully conditional specification in multivariate imputation.  J Stat Comput Simul. 2006;76(12):1049-1064. doi:10.1080/10629360600810434.Google ScholarCrossref
37.
Coresh  J, Turin  TC, Matsushita  K,  et al.  Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.  JAMA. 2014;311(24):2518-2531.PubMedGoogle ScholarCrossref
38.
Torres  VE, Chapman  AB, Devuyst  O,  et al; TEMPO 3:4 Trial Investigators.  Tolvaptan in patients with autosomal dominant polycystic kidney disease.  N Engl J Med. 2012;367(25):2407-2418.PubMedGoogle ScholarCrossref
39.
Sjöström  PA, Odlind  BG, Wolgast  M.  Extensive tubular secretion and reabsorption of creatinine in humans.  Scand J Urol Nephrol. 1988;22(2):129-131.PubMedGoogle ScholarCrossref
40.
Joppich  R, Deetjen  P.  The relation between the reabsorption of urea and of water in the distal tubule of the rat kidney.  Pflugers Arch. 1971;329(2):172-185.PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Topics
State Requirements